Increase in glycated haemoglobin concentrations after unwarranted prescription changes
- 8 June 2018
- journal article
- letter
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (10) , 2510-2511
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- SGLT‐2 inhibitors and the risk of lower‐limb amputation: Is this a class effect?Diabetes, Obesity and Metabolism, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Toe amputations with SGLT-2 inhibitors: data from randomized clinical trialsActa Diabetologica, 2016
- Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysisDiabetes, Obesity and Metabolism, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose ExcretionDiabetes Care, 2013
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ, 2000